

ASX Announcement

Racura Oncology & University of Wollongong granted NSW Government TechVoucher to study (E,E)-bisantrene in BRCA-mutated breast & ovarian cancers

- University of Wollongong and Racura Oncology have been granted funding under the NSW Government TechVouchers program to study the efficacy of (E,E)-bisantrene in *BRCA*-mutated breast and ovarian cancers
- Individuals with *BRCA* mutations have 70% cumulative risk of developing breast cancer by 80 years of age with *BRCA* mutations causing up to 25% of cancers in patients with a family history of breast or ovarian cancer
- Results of the collaboration are aimed at generating preclinical evidence for the clinical development of RC220 as a new targeted therapy for patients with *BRCA*-mutated cancers

29 April 2026

Racura Oncology Limited (“Racura”) is pleased to announce that the University of Wollongong and Racura Oncology have been awarded funding under the NSW Government TechVouchers Program for a project titled “*Efficacy of (E,E)-bisantrene (RCDS1) in BRCA-Mutated Cancers.*”¹

Loss-of-function mutations in breast cancer susceptibility genes 1 and 2 (*BRCA1* and *BRCA2*) predispose an individual to develop breast or ovarian cancer, with *BRCA*-mutation carriers having a 70% cumulative risk of developing breast cancer by 80 years of age.² *BRCA* mutations are responsible for up to 25% of all cancers in patients with a family history of breast or ovarian cancer.³

G-quadruplex-stabilising agents have been found to have heightened efficacy in *BRCA*-mutated tumours.⁴ Studies undertaken by Racura and collaborators have identified G-quadruplex stabilisation is the primary mechanism of action of (E,E)-bisantrene (ASX announcements: 2 October 2025 & 22 April 2026). This new preclinical collaboration is designed to evaluate the anticancer activity of (E,E)-bisantrene in preclinical

BRCA-mutated breast and ovarian cancer models and will be led by Dr Saurabh Satija at the University of Wollongong.

Racura Oncology CEO and Managing Director, Dr Daniel Tillett commented: *“Racura is grateful to the NSW Government for supporting this important research collaboration with the University of Wollongong. Individuals who have inherited BRCA mutations are at an extremely high risk of developing breast or ovarian cancer and there is a pressing need for improved treatment options.”*

University of Wollongong, Dr Saurabh Satija, commented: *“I’m really excited to work with Racura on this project. It’s a great opportunity to contribute to the development of new anti-cancer strategies and be part of work that has real potential to improve patient outcomes.”*

Dr Satija is an emerging oncology research leader with a strong track record in translational biomedical research, having published over 50 peer-reviewed articles, secured multiple patents, and been recognised among the world’s top 2% most cited researchers (2022–2025). Results from this collaboration will emerge over the next 12 months and are expected to be published in high impact scientific journal(s).

References

1. <https://www.nsw.gov.au/grants-and-funding/techvouchers>
2. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 Mutation carriers. JAMA. (2017) 317:2402–16.
3. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. (2019) 11:543–61.
4. Xu H, Di Antonio M, McKinney S, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun. (2017) 8:14432.

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au